VTRO (Vitro Biopharma) Notes Receivable: $0.00 Mil (As of Oct. 2022)


What is Vitro Biopharma Notes Receivable?

Vitro Biopharma VTRO Notes Receivable is $0.00 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's Notes Receivable for the quarter that ended in Oct. 2022 was $0.00 Mil.

Vitro Biopharma Notes Receivable Related Terms

Vitro Biopharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Notes Receivable Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vitro Biopharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Vitro Biopharma (VTRO) has a Notes Receivable of $0.00 Mil as of Oct. 2022. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's Notes Receivable too high?
Vitro Biopharma's current Notes Receivable is $0.00 Mil.
How does Vitro Biopharma's Notes Receivable compare to ?
Vitro Biopharma's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Notes Receivable is $0.00 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.